Comparison of the LIAISON (R) XL and ARCHITECT IgG, IgM, and IgG avidity assays for the diagnosis of Toxoplasma gondii, cytomegalovirus, and rubella virus infections

摘要

This study compared the performance of the LIAISON (R) XL system of immunoglobulin (Ig) G and IgM immunoassays for the diagnosis of Toxoplasma gondii, cytomegalovirus (CMV), and rubella virus infections with that of the ARCHITECT system. Patient serum samples, previously screened and clinically diagnosed with T gondii, CMV or rubella, were used to compare LIAISON (R) XL and ARCHITECT IgG and IgM immunoassays. LIAISON (R) XL Toxo and CMV IgG avidity assays were also compared with equivalent ARCHITECT assays and reference methods. Overall agreement between the LIAISON (R) XL and ARCHITECT assays was 99% and 92% for the Toxo IgG and IgM assays, respectively, 98% and 96% for the CMV IgG and IgM assays, respectively, and 93% and 98% for the rubella virus IgG and IgM assays, respectively. LIAISON (R) XL IgG Toxo and CMV avidity assays showed high concordance with the VIDAS (R) Toxo IgG avidity assay and an in-house CMV avidity assay (reference methods), and faster IgG avidity maturation in a larger number of samples collected months after the primary infection compared with equivalent ARCHITECT assays. LIAISON (R) XL assays for detection of anti-T. gondii, CMV and rubella virus IgG and IgM are at least equal to the competitor assays on the ARCHITECT platform.